Adial Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Adial Pharmaceuticals, Inc. (ADIL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2024-04-01
- Adial Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $2.00.
- Adial Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.00, a 96.67% decline from fiscal 2022.
- Adial Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.03, a 98.50% decline from fiscal 2021.
- Adial Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $2.00, a 0.50% increase from fiscal 2020.
- Adial Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $1.99.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $0.13 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $0.13 10-Q/A · filed 2023-10-30 | |||
| 2022-12-31 | $0.03 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-15 | |||
| 2021-12-31 | $2.00 10-K · filed 2022-03-28 | |||
| 2021-09-30 | $2.00 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $2.00 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $2.00 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $1.99 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |